We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
+7.82%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$250M
AUM Growth
+$5.97M
Cap. Flow
+$22.3M
Cap. Flow %
8.9%
Top 10 Hldgs %
93.7%
Holding
23
New
3
Increased
3
Reduced
3
Closed
4

Top Buys

1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$38.3M
2
ARGX icon
argenx
ARGX
+$13.5M
3
ASND icon
Ascendis Pharma A/S
ASND
+$4.62M
4
OBSV
ObsEva SA Ordinary Shares
OBSV
+$1.11M
5
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$1.01M

Top Sells

1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$21.9M
2
BOLD
Audentes Therapeutics, Inc
BOLD
+$7.82M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$2.8M
4
CHRS icon
Coherus Oncology
CHRS
+$2.02M
5
STML
Stemline Therapeutics, Inc.
STML
+$1.95M

Sector Composition

1 Healthcare 91.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$77M 30.74%
1,035,657
– –
BHVN
2
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$37.9M 15.15%
+1,664,300
New +$38.3M
ASND icon
3
Ascendis Pharma A/S
ASND
$17B
$27.4M 10.94%
986,492
+175,000
+22% +$4.62M
PDSB icon
4
PDS Biotechnology
PDSB
$39.8M
$19.8M 7.92%
96,679
– –
RARX
5
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$14.4M 5.76%
769,771
+44,742
+6% +$1.01M
BCRX icon
6
BioCryst Pharmaceuticals
BCRX
$2.31B
$13.8M 5.5%
2,475,167
-3,595,975
-59% -$21.9M
ARGX icon
7
argenx
ARGX
$53.7B
$13.6M 5.44%
+647,015
New +$13.5M
SIOX
8
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$7M 2.79%
37,715
-15,984
-30% -$2.8M
XLRN
9
DELISTED
Acceleron Pharma
XLRN
$4.77M 1.9%
156,880
– –
CTMX icon
10
CytomX Therapeutics
CTMX
$798M
$4.48M 1.79%
288,915
– –
ORKA
11
Oruka Therapeutics
ORKA
$5.01B
$2.59M 1.03%
4,995
– –
AKTX
12
Akari Therapeutics
AKTX
$20.1M
$1.97M 0.78%
533
+71
+15% +$561K
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$1.63M 0.65%
221,651
– –
LPCN icon
14
Lipocine
LPCN
$18.9M
$1.55M 0.62%
22,760
-1,946
-8% -$127K
OCRX
15
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.41M 0.56%
1,217,872
– –
OBSV
16
DELISTED
ObsEva SA Ordinary Shares
OBSV
$1.28M 0.51%
+150,000
New +$1.11M
ADVM
17
DELISTED
Adverum Biotechnologies
ADVM
$700K 0.28%
28,000
– –
SRRA
18
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$153K 0.06%
3,270
– –
ARCT icon
19
Arcturus Therapeutics
ARCT
$176M
– –
-26,449
Closed -$211K
CHRS icon
20
Coherus Oncology
CHRS
$214M
– –
-95,276
Closed -$2.02M
STML
21
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-228,130
Closed -$1.95M
BOLD
22
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-458,882
Closed -$7.82M

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q2 2017 Portfolio in Review

As of Q2 2017, VHCP Management II held 23 positions worth $250M, up 2.4% from $244M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

VHCP Management II deployed $22.3M of net new capital in Q2 2017, opening 3 new positions and adding to 3 existing holdings. Its largest new stake was Biohaven Pharmaceutical Holding Company Ltd.: 1,664,300 shares worth $37.9M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was BioCryst Pharmaceuticals, an estimated $21.9M trimmed.

  • VHCP Management II's largest Q2 2017 buy was Biohaven Pharmaceutical Holding Company Ltd.: 1,664,300 shares worth $37.9M.
  • VHCP Management II added most to Ascendis Pharma A/S in Q2 2017, an estimated $4.62M increase.
  • VHCP Management II's biggest Q2 2017 reduction was BioCryst Pharmaceuticals, cutting an estimated $21.9M.
  • VHCP Management II fully exited Audentes Therapeutics, Inc in Q2 2017, selling an estimated $7.82M.
  • VHCP Management II's ten largest holdings make up 94% of its $250M portfolio in Q2 2017.
  • VHCP Management II opened 3 new positions and closed 4 in Q2 2017.
  • VHCP Management II's portfolio value rose 2.4% quarter-over-quarter to $250M.

Based on VHCP Management II's 13F filing for Q2 2017, filed 11 Aug 2017.